Chemical Structure : LCI133
货号: PC-25672Not For Human Use, Lab Use Only.
LCI133 is a highly potent, selective multikinase CDK4/6/9 and AURKA/B inhibitor with IC50 of 4.7/10.2/4.1 nM for CDK4/6/9 and 2.8/10.6 nM for AURKA/B.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
LCI133 is a highly potent, selective multikinase CDK4/6/9 and AURKA/B inhibitor with IC50 of 4.7/10.2/4.1 nM for CDK4/6/9 and 2.8/10.6 nM for AURKA/B.
LCI133 shows minimal inhibition of PI3Kδ with IC50 of 897 nM, has littile to no activity against CDK2/cyclin E, CDK7/cyclin H and DNA-PK.
LCI133 is cytotoxic to multiple cancer cell lines, arrests the cell cycle, and induces apoptosis.
LCI133 has IC50 of 0.17, 0.21, 0.19, 0.34, and 0.55 μM, in human MYCN-amplified and nonamplified NB cell lines (BE(2)-C, NGP, Kelly, SK-N-AS, and SHEP, respectively), also exhibits submicromolar activity in MCL (Jeko-1 and Mino), prostate cancer (22Rv1), and endometrial cancer (AN3 CA) cellular models.
LCI133 blocks CDK9 signaling axis and suppresses MYCN and MCL-1 transcription in MYCN-amplified neuroblastoma (NB).
LCI133 (40 mg/kg/day, i.p.) significantly reduces the growth of BE(2)-C xenografted tumors without notable change in behavior or mouse body weight.
| 分子量 | 578.67 | |
| 分子式 | C33H34N6O4 | |
| 外观性状 | Solid | |
| 储存条件 |
|
|
| Solubility |
10 mM in DMSO |
|
1. Maddeboina K, et al. J Med Chem. 2025 Nov 6. doi: 10.1021/acs.jmedchem.5c01688.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright